Leavitt, Blair R.

Huntington disease

Bates, G. P., Dorsey, R., Gusella, J. F., Hayden, M. R., Kay, C., Leavitt, B. R., Nance, M., Ross, C. A., Scahill, R. I., Wetzel, R., et al. (2015) · Nature Reviews Disease Primers

Genetic Neurodegenerative DiseasesHereditary Neurological Disorders

Cited by 1,641

The current landscape of nucleic acid therapeutics

Kulkarni, J. A., Witzigmann, D., Thomson, S. B., Chen, S., Leavitt, B. R., Cullis, P. R., & van der Meel, R. (2021) · Nature Nanotechnology

RNA Interference and Gene DeliveryNanoparticle-Based Drug Delivery

Cited by 1,371

Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines

Panov, A. V., Gutekunst, C.-A., Leavitt, B. R., Hayden, M. R., Burke, J. R., Strittmatter, W. J., & Greenamyre, J. T. (2002) · Nature Neuroscience

Genetic Neurodegenerative DiseasesMitochondrial Function and Pathology

Cited by 1,030

Huntington disease: natural history, biomarkers and prospects for therapeutics

Ross, C. A., Aylward, E. H., Wild, E. J., Langbehn, D. R., Long, J. D., Warner, J. H., Scahill, R. I., Leavitt, B. R., Stout, J. C., Paulsen, J. S., et al. (2014) · Nature Reviews Neurology

Genetic Neurodegenerative DiseasesDeep Brain Stimulation and Movement Disorders

Cited by 1,016

Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data

Tabrizi, S. J., Langbehn, D. R., Leavitt, B. R., Roos, R. A., Durr, A., Craufurd, D., Kennard, C., Hicks, S. L., Fox, N. C., Scahill, R. I., et al. (2009) · The Lancet Neurology

Genetic Neurodegenerative DiseasesDeep Brain Stimulation and Movement Disorders

Cited by 984

Huntingtin interacts with REST/NRSF to modulate the transcription of NRSE-controlled neuronal genes

Zuccato, C., Tartari, M., Crotti, A., Goffredo, D., Valenza, M., Conti, L., Cataudella, T., Leavitt, B. R., Hayden, M. R., Timmusk, T., et al. (2003) · Nature Genetics

Genetic Neurodegenerative DiseasesGenetics and Neurodevelopmental Disorders

Cited by 979

Targeting Huntingtin Expression in Patients with Huntington’s Disease

Tabrizi, S. J., Leavitt, B. R., Landwehrmeyer, G. B., Wild, E. J., Saft, C., Barker, R. A., Blair, N. F., Craufurd, D., Priller, J., Rickards, H., et al. (2019) · New England Journal of Medicine

Genetic Neurodegenerative DiseasesLysosomal Storage Disorders Research

Cited by 708

Neurofilament light protein in blood as a potential biomarker of neurodegeneration in Huntington's disease: a retrospective cohort analysis

Byrne, L. M., Rodrigues, F. B., Blennow, K., Durr, A., Leavitt, B. R., Roos, R. A. C., Scahill, R. I., Tabrizi, S. J., Zetterberg, H., Langbehn, D., et al. (2017) · The Lancet Neurology

Genetic Neurodegenerative DiseasesHereditary Neurological Disorders

Cited by 364

Identification of genetic variants associated with Huntington's disease progression: a genome-wide association study

Moss, D. J. H., Pardiñas, A. F., Langbehn, D., Lo, K., Leavitt, B. R., Roos, R., Durr, A., Mead, S., Coleman, A., Santos, R. D., et al. (2017) · The Lancet Neurology

Genetic Neurodegenerative DiseasesGenetic Associations and Epidemiology

Cited by 312

Human ABCA1 BAC Transgenic Mice Show Increased High Density Lipoprotein Cholesterol and ApoAI-dependent Efflux Stimulated by an Internal Promoter Containing Liver X Receptor Response Elements in Intron 1

Singaraja, R. R., Bocher, V., James, E. R., Clee, S. M., Zhang, L.-H., Leavitt, B. R., Tan, B., Brooks-Wilson, A., Kwok, A., Bissada, N., et al. (2001) · Journal of Biological Chemistry

Cholesterol and Lipid MetabolismDrug Transport and Resistance Mechanisms

Cited by 194

Progranulin expression in the developing and adult murine brain

Petkau, T. L., Neal, S. J., Orban, P. C., MacDonald, J. L., Hill, A. M., Lu, G., Feldman, H. H., Mackenzie, I. R. A., & Leavitt, B. R. (2010) · Journal of Comparative Neurology

Amyotrophic Lateral Sclerosis ResearchNeuroinflammation and Neurodegeneration Mechanisms

Cited by 152

KEAP1-modifying small molecule reveals muted NRF2 signaling responses in neural stem cells from Huntington's disease patients

Quinti, L., Dayalan Naidu, S., Träger, U., Chen, X., Kegel-Gleason, K., Llères, D., Connolly, C., Chopra, V., Low, C., Moniot, S., et al. (2017) · Proceedings of the National Academy of Sciences

Genomics, phytochemicals, and oxidative stressGenetic Neurodegenerative Diseases

Cited by 140

A SNP in the HTT promoter alters NF-κB binding and is a bidirectional genetic modifier of Huntington disease

REGISTRY Investigators of the European Huntington's Disease Network, Bečanović, K., Nørremølle, A., Neal, S. J., Kay, C., Collins, J. A., Arenillas, D., Lilja, T., Gaudenzi, G., Manoharan, S., et al. (2015) · Nature Neuroscience

Genetic Neurodegenerative DiseasesLysosomal Storage Disorders Research

Cited by 135

Antisense oligonucleotides for neurodegeneration

Leavitt, B. R., & Tabrizi, S. J. (2020) · Science

Amyotrophic Lateral Sclerosis ResearchAlzheimer's disease research and treatments

Cited by 96

Potential biomarkers to follow the progression and treatment response of Huntington’s disease

Disatnik, M.-H., Joshi, A. U., Saw, N. L., Shamloo, M., Leavitt, B. R., Qi, X., & Mochly-Rosen, D. (2016) · Journal of Experimental Medicine

Genetic Neurodegenerative DiseasesMitochondrial Function and Pathology

Cited by 58

Mutant huntingtin expression in microglia is neither required nor sufficient to cause the Huntington's disease-like phenotype in BACHD mice

Petkau, T. L., Hill, A., Connolly, C., Lu, G., Wagner, P., Kosior, N., Blanco, J., & Leavitt, B. R. (2019) · Human Molecular Genetics

Genetic Neurodegenerative DiseasesNeuroinflammation and Neurodegeneration Mechanisms

Cited by 37

Direct intracerebral delivery of a miR-33 antisense oligonucelotide into mouse brain increases brain ABCA1 expression

Jan, A., Karasinska, J. M., Kang, M. H., de Haan, W., Ruddle, P., Kaur, A., Connolly, C., Leavitt, B. R., Sorensen, P. H., & Hayden, M. R. (2015) · Neuroscience Letters

Cholesterol and Lipid MetabolismRNA Interference and Gene Delivery

Cited by 28

Effects of IONIS-HTTRx in Patients with Early Huntington’s Disease, Results of the First HTT-Lowering Drug Trial (CT.002)

Tabrizi, S., Leavitt, B., Kordasiewicz, H., Czech, C., Swayze, E., Norris, D. A., Baumann, T., Gerlach, I., Schobel, S., Smith, A., et al. (2018) · Neurology

Genetic Neurodegenerative DiseasesAmyotrophic Lateral Sclerosis Research

Cited by 26